Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIDA CRADA with Reckitt & Colman Pharmaceuticals

Executive Summary

The National Institute on Drug Abuse is contemplating a CRADA with Richmond, Va.-based Reckitt & Colman Pharmaceuticals to license sublingual dosage forms of buprenorphine -- in combination with naloxone or alone -- for the treatment of opiate dependence, May 12 Federal Register notice states. Reckitt & Colman markets the opioid analgesic Buprenex (buprenorphine) injectable for the relief of moderate to severe pain.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022622

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel